TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE GLOBAL THYROID CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 49
1.5 MARKETS COVERED 49
2 MARKET SEGMENTATION 52
2.1 MARKETS COVERED 52
2.2 GEOGRAPHICAL SCOPE 53
2.3 YEARS CONSIDERED FOR THE STUDY 54
2.4 CURRENCY AND PRICING 54
2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
2.6 MULTIVARIATE MODELLING 58
2.7 PRODUCT TYPE LIFELINE CURVE 58
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
2.9 DBMR MARKET POSITION GRID 60
2.10 MARKET TESTING TYPE COVERAGE GRID 62
2.11 VENDOR SHARE ANALYSIS 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHTS 68
4.1 PESTEL ANALYSIS 71
4.2 PORTERS FIVE FORCES 72
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 73
5 EPIDEMIOLOGY 74
6 REGULATORY FRAMEWORK OF THE GLOBAL THYROID CANCER DIAGNOSTICS MARKET 75
6.1 REGULATORY SCENARIO IN THE U.S. 75
6.2 REGULATORY SCENARIO IN AUSTRALIA 76
6.3 REGULATORY SCENARIO IN JAPAN 76
6.4 REGULATORY SCENARIO IN CHINA 76
7 MARKET OVERVIEW 77
7.1 DRIVERS 79
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 79
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 79
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 80
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 80
7.2 RESTRAINTS 81
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 81
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 82
7.3 OPPORTUNITIES 82
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 82
7.3.2 RISING OBESE POPULATION 83
7.4 CHALLENGES 83
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 83
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 84
8 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 85
8.1 OVERVIEW 86
8.2 INSTRUMENTS 89
8.2.1 PATHOLOGY BASED INSTRUMENTS 90
8.2.1.1 PCR INSTRUMENTS 90
8.2.1.2 SLIDE STAINING SYSTEMS 90
8.2.1.3 TISSUE PROCESSING SYSTEMS 90
8.2.1.4 CELL PROCESSORS 91
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 91
8.2.2 IMAGING INSTRUMENTS 91
8.2.2.1 ULTRASOUND SYSTEMS 91
8.2.2.2 CT SYSTEMS 91
8.2.2.3 MRI SYSTEMS 91
8.2.2.4 OTHERS 91
8.2.3 BIOPSY INSTRUMENTS 92
8.2.3.1 NEEDLE BIOPSY 92
8.2.3.2 ENDOSCOPIC BIOPSY 92
8.2.3.3 CORE BIOPSY 92
8.2.3.4 OTHERS 92
8.2.4 OTHERS 92
8.3 CONSUMABLES & ACCESSORIES 93
8.3.1 KITS 94
8.3.1.1 PCR KITS 94
8.3.1.2 DNA POLYMERASE KITS 94
8.3.1.3 NUCLEIC ACID ISOLATION KITS 94
8.3.1.4 OTHERS 94
8.3.2 REAGENTS 95
8.3.2.1 ASSAYS 95
8.3.2.2 BUFFERS 95
8.3.2.3 PRIMERS 95
8.3.2.4 OTHERS 95
8.3.3 PROBES 95
8.3.4 OTHER CONSUMABLES 95
9 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 96
9.1 OVERVIEW 97
9.2 IMAGING TEST 100
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 101
9.2.2 MRI 101
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 101
9.2.4 OTHERS 101
9.3 BLOOD TEST 102
9.3.1 BLOOD CHEMISTRY TESTS 103
9.3.2 COMPLETE BLOOD COUNT (CBC) 103
9.3.3 OTHERS 103
9.4 BIOPSY 103
9.4.1 NEEDLE BIOPSY 104
9.4.2 BRONCHOSCOPY BIOPSY 104
9.4.3 CORE BIOPSY 104
9.4.4 OTHERS 104
9.5 OTHERS 105
10 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 106
10.1 OVERVIEW 107
10.2 PAPILLARY CARCINOMA 110
10.3 FOLLICULAR CARCINOMA 111
10.4 OTHERS 112
11 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 113
11.1 OVERVIEW 114
11.2 STAGE I 117
11.3 STAGE II 118
11.4 STAGE III 119
11.5 STAGE IV 120
12 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 121
12.1 OVERVIEW 122
12.2 30-65 125
12.3 65 AND ABOVE 126
12.4 21-29 127
12.5 BELOW 21 128
13 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY END USER 129
13.1 OVERVIEW 130
13.2 HOSPITALS 133
13.3 ASSOCIATED LABS 134
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 134
13.5 DIAGNOSTIC IMAGING CENTERS 135
13.6 CANCER RESEARCH INSTITUTES 136
13.7 OTHERS 137
14 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 138
14.1 OVERVIEW 139
14.2 DIRECT TENDER 142
14.3 RETAIL SALES 143
15 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY REGION 144
15.1 OVERVIEW 145
15.2 NORTH AMERICA 151
15.2.1 U.S. 161
15.2.2 CANADA 166
15.2.3 MEXICO 171
15.3 EUROPE 176
15.3.1 GERMANY 186
15.3.2 U.K. 191
15.3.3 ITALY 196
15.3.4 FRANCE 201
15.3.5 SPAIN 206
15.3.6 RUSSIA 211
15.3.7 SWITZERLAND 216
15.3.8 TURKEY 221
15.3.9 BELGIUM 226
15.3.10 NETHERLANDS 231
15.3.11 REST OF EUROPE 236
15.4 ASIA-PACIFIC 237
15.4.1 JAPAN 247
15.4.2 CHINA 252
15.4.3 SOUTH KOREA 258
15.4.4 INDIA 263
15.4.5 THAILAND 268
15.4.6 SINGAPORE 273
15.4.7 INDONESIA 278
15.4.8 MALAYSIA 283
15.4.9 PHILIPPINES 288
15.4.10 AUSTRALIA 294
15.4.11 VIETNAM 299
15.4.12 REST OF ASIA-PACIFIC 304
15.5 SOUTH AMERICA 305
15.5.1 BRAZIL 316
15.5.2 ARGENTINA 321
15.5.3 REST OF SOUTH AMERICA 327
15.6 MIDDLE EAST AND AFRICA 328
15.6.1 SAUDI ARABIA 339
15.6.2 U.A.E. 344
15.6.3 SOUTH AFRICA 349
15.6.4 EGYPT 355
15.6.5 ISRAEL 360
15.6.6 REST OF MIDDLE EAST AND AFRICA 365
16 GLOBAL THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 366
16.1 COMPANY SHARE ANALYSIS: GLOBAL 366
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 367
16.3 COMPANY SHARE ANALYSIS: EUROPE 368
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 369
17 SWOT ANALYSIS 370
18 COMPANY PROFILE 371
18.1 CANON INC. 371
18.1.1 COMPANY SNAPSHOT 371
18.1.2 COMPANY SHARE ANALYSIS 371
18.1.3 PRODUCT PORTFOLIO 372
18.1.4 RECENT DEVELOPMENTS 372
18.2 FUJIFILM CORPORATION 373
18.2.1 COMPANY SNAPSHOT 373
18.2.2 REVENUE ANALYSIS 373
18.2.3 COMPANY SHARE ANALYSIS 374
18.2.4 PRODUCT PORTFOLIO 374
18.2.5 RECENT DEVELOPMENT 374
18.3 F. HOFFMANN-LA ROCHE LTD 375
18.3.1 COMPANY SNAPSHOT 375
18.3.2 REVENUE ANALYSIS 375
18.3.3 COMPANY SHARE ANALYSIS 376
18.3.4 PRODUCT PORTFOLIO 376
18.3.5 RECENT DEVELOPMENT 376
18.4 QUEST DIAGNOSTICS INCORPORATED 377
18.4.1 COMPANY SNAPSHOT 377
18.4.2 REVENUE ANALYSIS 377
18.4.3 COMPANY SHARE ANALYSIS 378
18.4.4 PRODUCT PORTFOLIO 378
18.4.5 RECENT DEVELOPMENTS 378
18.5 ILLUMINA, INC. 380
18.5.1 COMPANY SNAPSHOT 380
18.5.2 REVENUE ANALYSIS 380
18.5.3 COMPANY SHARE ANALYSIS 381
18.5.4 PRODUCT PORTFOLIO 381
18.5.5 RECENT DEVELOPMENT 381
18.6 ABBOTT 382
18.6.1 COMPANY SNAPSHOT 382
18.6.2 REVENUE ANALYSIS 382
18.6.3 PRODUCT PORTFOLIO 383
18.6.4 RECENT DEVELOPMENT 383
18.7 BD 384
18.7.1 COMPANY SNAPSHOT 384
18.7.2 REVENUE ANALYSIS 384
18.7.3 PRODUCT PORTFOLIO 385
18.7.4 RECENT DEVELOPMENT 385
18.8 BEIJING O&D BIOTECH CO., LTD. 386
18.8.1 COMPANY SNAPSHOT 386
18.8.2 PRODUCT PORTFOLIO 386
18.8.3 RECENT DEVELOPMENTS 386
18.9 BIOMRIEUX SA 387
18.9.1 COMPANY SNAPSHOT 387
18.9.2 REVENUE ANALYSIS 387
18.9.3 PRODUCT PORTFOLIO 388
18.9.4 RECENT DEVELOPMENTS 388
18.10 DIASORIN S.P.A. 389
18.10.1 COMPANY SNAPSHOT 389
18.10.2 REVENUE ANALYSIS 389
18.10.3 PRODUCT PORTFOLIO 390
18.10.4 RECENT DEVELOPMENT 390
18.11 FONAR CORP. 391
18.11.1 COMPANY SNAPSHOT 391
18.11.2 REVENUE ANALYSIS 391
18.11.3 PRODUCT PORTFOLIO 392
18.11.4 RECENT DEVELOPMENTS 392
18.12 GENERAL ELECTRIC 393
18.12.1 COMPANY SNAPSHOT 393
18.12.2 REVENUE ANALYSIS 393
18.12.3 PRODUCT PORTFOLIO 394
18.12.4 RECENT DEVELOPMENTS 394
18.13 HOLOGIC INC. 395
18.13.1 COMPANY SNAPSHOT 395
18.13.2 REVENUE ANALYSIS 395
18.13.3 PRODUCT PORTFOLIO 396
18.13.4 RECENT DEVELOPMENT 396
18.14 KONINKLIJKE PHILIPS N.V. 397
18.14.1 COMPANY SNAPSHOT 397
18.14.2 REVENUE ANALYSIS 397
18.14.3 PRODUCT PORTFOLIO 398
18.14.4 RECENT DEVELOPMENT 398
18.15 MERCK KGAA. 399
18.15.1 COMPANY SNAPSHOT 399
18.15.2 REVENUE ANALYSIS 399
18.15.3 PRODUCT PORTFOLIO 400
18.15.4 RECENT DEVELOPMENT 400

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.